Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib

Journal of Investigative Dermatology

Volumn 137, Issue 4, 2017, Pages 951-954

  King, Brett ^a   Lee, Alfred Ian ^a   Choi, Jaehyuk ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; PROGESTERONE; RUXOLITINIB; TOFACITINIB; JANUS KINASE INHIBITOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BLOOD; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FURUNCULOSIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MORNING DOSAGE; MYELOPROLIFERATIVE NEOPLASM; PERIPHERAL CIRCULATION; RASH; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; COMPLICATION; SKIN DISEASE;

ADULT; AGED; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; JANUS KINASE INHIBITORS; MALE; MIDDLE AGED; PIPERIDINES; PYRAZOLES; PYRIMIDINES; PYRROLES; SKIN DISEASES;

EID: 85015956860     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.10.044     Document Type: Article

References (9)

1. Gotlib, J., World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol 89 (2014), 325–337.
2. Keohane, C., Kordasti, S., Seidl, T., Perez Abellan, P., Thomas, N.S., Harrison, C.N., et al. JAK inhibition induces silencing of T helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol 171 (2015), 60–73.
3. Klion, A.D., How I treat hypereosinophilic syndromes. Blood 126 (2015), 1069–1077.
4. Klion, A.D., Bochner, B.S., Gleich, G.J., Nutman, T.B., Rothenberg, M.E., Simon, H.U., et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117 (2006), 1292–1302.
5. Roufosse, F., Cogan, E., Goldman, M., Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 27 (2007), 389–413.
6. Simon, H.U., Plotz, S.G., Dummer, R., Blaser, K., Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 (1999), 1112–1120.
7. Stritesky, G.L., Muthukrishnan, R., Sehra, S., Goswami, R., Pham, D., Travers, J., et al. The transcription factor STAT3 is required for T helper 2 cell development. Immunity 34 (2011), 39–49.
8. Valent, P., Klion, A.D., Horny, H.P., Roufosse, F., Gotlib, J., Weller, P.F., et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130 (2012), 607–612.e9.
9. Walker, S., Wang, C., Walradt, T., Hong, B.S., Tanner, J.R., Levinsohn, J.L., et al. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood 127 (2016), 948–951.